eurekalert.org
Cure8 news brief
Why This Matters
This study suggests a different treatment target for Crohn’s disease: fixing damaged intestinal lining rather than only suppressing inflammation. If validated in humans, repurposed cancer drugs could speed development of therapies that help the gut barrier heal.
Who Should Pay Attention
Patients with Crohn's disease, clinicians treating IBD, and researchers working on epithelial biology, drug repurposing, or translational gastroenterology.
Study Snapshot
Story typePress release
Evidence typeClinical study
Source depthFull source text
What To Know
University of Houston-led researchers report lab findings that Crohn’s disease may be driven by persistent stress signaling in intestinal epithelial cells that prevents normal repair.
In patient-derived organoids, low doses of two existing cancer drugs (pazopanib and ponatinib) reduced that stress signaling and cell death, and promoted epithelial regeneration.
The team frames this as shifting focus from immune suppression to restoring the gut barrier, and highlights the potential advantage of repurposing FDA-approved cancer drugs to shorten development time. The work used patient-derived organoids and was published in Gastro Hep Advances.
This is preclinical research (lab and organoid experiments) describing a possible therapeutic approach; it does not report results from human clinical trials or change current treatment recommendations.
Keep In Mind
Early-stage, preclinical research using patient-derived organoids; results do not equal clinical efficacy yet and further trials would be needed. The article is a university press release summarizing a study published in Gastro Hep Advances.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationeurekalert.org
Indexed viaGoogle News
Source typePress release
PublishedApr 27, 2026, 8:08 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn's ...
The story describes a new drug mechanism (dCK inhibition) that reduced inflammation in an IBD mouse model, which could point to a different way to target overactive immune cells in Crohn’s disease. It’s early-stage...
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
Patients with Crohn’s disease and other IBD forms may see new research directions aimed at blocking immune cell proliferation by targeting nucleotide metabolism. This is early-stage, preclinical work presented at a...
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.